– USA, MA – Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.
“Anil’s deep experience in oncology and his track record of product launch and commercial operations excellence will be invaluable as Verastem works to bring its lead compound RAF/MEK clamp VS-6766 in combinations across RAS-driven tumors to patients. I am pleased to welcome Anil to the Board of Directors and believe he will be a tremendous source of strategic insights and guidance,” said Lead Director, Dr. Mike Kauffman.
About Anil Kapur
Mr. Kapur is the EVP of Corporate Strategy and CCO at Geron Corporation.
Anil Kapur is an experienced executive with more than 25 years of experience in pharmaceutical and biotech companies across both US and international markets. He has held senior leadership positions overseeing the launch of significant global brands, building and managing commercial capabilities in small and large organizations, driving corporate strategy, and managing alliances.
Before Geron, Mr. Kapur served as the CCO at Actinium Pharmaceuticals, Inc. and as VP, Head of Early Assets, Biomarkers, and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb Company. Previously, Mr. Kapur was VP, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, which Shire PLC acquired in 2016. Before joining Baxalta, Mr. Kapur served as VP, Commercial Leader Hematology Franchise at Johnson & Johnson’s global pharmaceutical strategy organization and in various sales and marketing leadership roles.
“I’m looking forward to joining Verastem’s Board of Directors as the Company works to advance its development program toward potential market availability in recurrent low-grade serous ovarian cancer, an area of unmet need,” said Anil Kapur. “I am excited to combine my experience with the important progress the Company is making in addressing difficult-to-treat RAS pathway-driven tumors through combinations with VS-6766.”
Mr. Kapur holds a BE from the Birla Institute of Technology in India, an MS in Industrial Engineering from Louisiana Tech University, and an MBA from the Fuqua School of Business at Duke University.
About Verastem Oncology
Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase inhibition.
For more information: https://www.verastem.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
